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Abstract 
Preterm birth (PTB) remains the most serious 
complication in obstetrics and a substantial 
excess burden in US healthcare economics. The 
etiology of PTB is complex and likely has 
multiple physiological pathways. Unfortunately, 
current antenatal care screening methods have 
not been successful in predicting and, 
eventually, preventing PTB. 
Although treatments such as progesterone, 
cerclage and pessary are available for patients 
with historical risk factors and shortened cervix, 
these treatments are not universally efficacious. 
Antenatal care is in great need of new prediction 
and prevention strategies. 
The role of more global methods of screening 
and treatment is still undefined. Most women 
with clinical risk factors will not deliver early, and 
aggressive interventions in large segments of 
the population may not be warranted or cost 
effective. Furthermore, over half of women who 
experience PTB have no historical risk factors. 
Even second-trimester cervical length (CL) has 
only modest ability to predict which women will 
experience PTB. 
There is thus a clear need to identify biomarkers 
that provide quantitative, individualized 
assessment of risk early in pregnancy that is 
specific for each individual woman. The ideal 
biomarkers would be indicative of the pathway 
leading to PTB, require no special testing 
equipment, have a low false positive and 
negative rate, and offer early identification, 
allowing adequate time to intervene. We need 
an aggressive and comprehensive approach to 
see a dramatic reduction in rates of preterm 
delivery in the U.S. 
1Division of Maternal-Fetal Medicine of the 
Department of Obstetrics & Gynecology at the 
Medical University of South Carolina, 
Charleston, SC. 
2Department of Obstetrics and Gynecology and 
the Division of Education and Research for the 
Christiana Care Health System, Newark, DE. 
3Maternal Fetal Medicine at Valley Perinatal 
Services and Banner Good Samaritan Medical 
Center in Phoenix, AZ. 
 
 
Recent media reports have praised 
several states (Iowa, Virginia, Arkansas, 
Nevada and Oklahoma) for achieving 
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reductions in the rate of preterm birth 
(PTB).1  Though these reports represent 
progress, we must acknowledge that the 
current rate of 9.6% in the US, which is 
the highest among developed countries, 
is unacceptable, and that our current 
thinking about PTB requires revision.2 
Preterm Birth as a Public Health 
Issue 
PTB remains the most serious 
complication in obstetrics and a 
substantial excess burden in US 
healthcare economics.  In addition, it 
accounts for 85% of neonatal morbidity 
and mortality worldwide,3 is a leading 
cause of death in children <5 years of 
age, is responsible for nearly 1 million 
deaths per year, and a leading cause of 
chronic disability, straining the Medicaid 
budgets of most states.4,5 Persistent and 
wide disparities in PTB also exist, 
especially for Africa-American women.  
1The rate of PTB increased in the United 
States until 2006, is now declining 
slightly.   
Currently, the average cost of a stay in a 
neonatal intensive care unit (NICU) 
exceeds $10,000 for infants born at 34 
weeks’ gestation and is greater than 
$100,000 for those born at 28 weeks or 
earlier.6 In the United States, over $26 
billion per year is spent on PTB.7 This 
estimate is likely low, as it does not 
include the costs of long-term care due 
to ongoing sequelae, which are 
significantly higher than the acute 
costs.7,8 Children affected by the 
consequences of PTB may face ongoing 
intellectual impairments, learning 
difficulties, motor deficits, other chronic 
medical issues, and reduced prospects 
for employment. Economic analyses 
alone do not fully capture the emotional 
and financial burdens to children and 
their families. 
While some states and the March of 
Dimes are attempting to increase 
awareness of PTB, there is still 
insufficient media focus and public 
outcry about the emotional and financial 
costs and impact on society associated 
with PTB. Considering the serious 
consequences of PTB, public 
awareness of the problem is surprisingly 
low! 
PTB may be spontaneous or iatrogenic, 
usually medically indicated.  The recent 
downward trends of PTB rate has been 
weighted toward iatrogenic PTB and 
minimally impacted the early gestational 
age births, the children primarily born 
with short-term as well as long-term 
economic, physical, and emotional 
implications. 
Challenges We Face 
The etiology of spontaneous PTB is 
complex and likely has multiple 
physiological pathways.  Unfortunately, 
current antenatal care screening 
methods have not been successful in 
predicting and, eventually, preventing 
PTB. In the majority of cases of PTB, 
our current approach is usually limited to 
waiting for symptoms of preterm labor 
(PTL) to occur, attempting to decrease 
the frequency and strength of 
contractions, administering steroids and, 
if appropriate, transferring patients to 
facilities with high-level neonatal care. 
However, this focus on preterm labor 
(PTL) has met with limited success. 
Contractions, rupture of membranes, 
and labor are late events in the 
physiologic cascade leading to PTB.9 
Uterine activity may not be evident until 
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weeks after modulation of progesterone 
receptors, activation of decidua, 
overexpression of proinflammatory 
cytokines, and cervical remodeling have 
begun.9,10 When uterine contractions or 
cervical changes are present, the 
physiologic process of PTB may have 
been ongoing for several weeks. 
Although treatments such as 
progesterone, cerclage and pessary are 
available for patients with historical risk 
factors and shortened cervix, these 
treatments are not universally 
efficacious. Antenatal care is in great 
need of new prediction and prevention 
strategies. 
Addressing individual risk factors alone 
is unlikely to make a large impact. In a 
review across 39 countries, the only 
effective interventions noted were 
smoking cessation, decreased number 
of embryo transfers during assisted 
reproduction, cerclage, progesterone, 
and reducing nonmedically-indicated 
deliveries.11 However, application of 
these interventions proved to be of 
limited value. The expected overall 
change in the rate of PTB from using 
these interventions was calculated to 
result in a 0.52% decrease in the overall 
rate of PTB. 
The role of more global methods of 
screening and treatment is still 
undefined. Petrini, et al., estimated that 
using current treatment strategies such 
as progesterone treatment in all women 
with a history of PTB would only lower 
the overall rate of PTB by 0.3%.12 Most 
women with clinical risk factors will not 
deliver early, and aggressive 
interventions in large segments of the 
population may not be warranted or cost 
effective.13 Furthermore, over half of 
women who experience PTB have no 
historical risk factors. Even second-
trimester cervical length (CL) has only 
modest ability to predict which women 
will experience PTB.13,14,15 
There is thus a clear need to identify 
biomarkers that provide quantitative, 
individualized assessment of risk early 
in pregnancy that is specific for each 
individual woman. The ideal biomarkers 
would be indicative of the pathway 
leading to PTB, require no special 
testing equipment, have a low false 
positive and negative rate, and offer 
early identification, allowing adequate 
time to intervene.   
In parallel, we must redouble our efforts 
to optimize current treatments, invest in 
development of new interventions and 
focus on incremental improvements in 
neonatal health and cost reduction. 
Although effective primary prevention 
has not yet been developed, secondary 
prevention (assessment of risk factors, 
screening for CL, and treatment of 
bacteriuria and other infections 
associated with PTB) and tertiary 
prevention (ensuring administration of 
corticosteroids and proximity to a NICU) 
are strategies still available. The 
ultimate measure of the benefit of an 
intervention is whether it: (1) improves 
the short-term and long-term health of 
the child, and (2) and lowers health care 
costs when applied to the general 
population. 
Screening 
Clinical Risk Assessment 
The clinician’s primary task is to 
ascertain the risk factors for PTB in the 
individual patient and address 
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preventable causes. Screening for risk 
factors from a woman’s past medical, 
family and pregnancy history is 
inexpensive, requires no technology, 
and can begin at the preconception visit 
or the first prenatal visit. 
The single most important risk factor for 
PTB and the one most likely to alter 
medical management is a history of a 
previous spontaneous PTB.16 A woman 
with a single previous PTB has a 16% 
risk for PTB at <35 weeks’ gestation.17 
A woman with 2 previous PTBs has a 
41% risk for PTB, and a woman with 3 
previous PTBs has a 67% risk. Family 
history of PTB is an additional risk 
factor, as is multiple gestation, 60% of 
whom experience PTB.18 
Many historical, social, behavioral, and 
medical risk factors for PTB have been 
reported in the literature (Table 
1).9,13,15,19-21 Simple questions as part of 
the screening form may uncover 
modifiable risk factors, such as smoking 
and substance abuse, and social risk 
factors that can be addressed by 
offering adequate support services, 
which are readily available in most 
communities but not adequately 
accessed by women who would benefit 
from these services to modify risk. Of 
note, the majority of patients surveyed 
by the Pregnancy Risk Assessment 
Monitoring System who reported a need 
for help with domestic violence or 
substance abuse did not receive 
assistance for modifying this risk.22   
Unfortunately, many risk factors apply to 
large proportions of the population and 
are too imprecise to be useful for 
guiding direct individual interventions, as 
most women who have them will not 
have PTB.23 At present, risk factors 
alone cannot effectively predict the risk 
for PTB among primigravidas. And even 
with more effective screening, it remains 
that all women are at risk for PTB, as 
evidenced by the fact that 50% of PTB 
occurs in women with no apparent risk 
factors for PTB.24   
Table 1. Risk Factors for 
Spontaneous Preterm Birth 
Historical 
 
Personal history of preterm birth 
Family history of preterm birth 
Short inter birth interval 
Cervical surgery 
Recurrent first or second trimester loss 
African descent 
Maternal age 
 
Medical 
 
Maternal body mass index 
Transfer of multiple embryos 
Multiple gestation 
Urinary tract infection 
Cervicitis 
Dental problems 
Short cervical length 
Vaginal bleeding 
 
Social 
 
Low socioeconomic status 
Lack of social support 
Domestic violence 
Lack of food security 
Poverty 
High level of stress 
Literacy 
 
Behavioral 
 
Smoking  
Substance abuse 
Recent change of domicile 
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Cervical Length 
Regular monitoring of CL has been 
suggested for women with a history of 
PTB, with cerclage placement offered 
based on CL.22,25,26,27,28 
Universal CL screening at 18 to 20 
weeks’ gestation for women without risk 
factors for PTB is hotly debated.29-32 
Some authors have demonstrated a 
cost benefit for universal screening 
based on decision analyses30 with the 
belief that early detection of cervical 
shortening may allow time for 
intervention before PTL begins. 
Although universal screening for CL is 
not currently recommended, it may be a 
reasonable way to screen women who 
do not have a prior pregnancy history. 
Even so, it fails to detect 26% of PTB 
cases.26  
Universal CL screening is warranted if it 
results in better outcomes and lower 
costs. CL screening could be a major 
step toward identifying women who 
deliver preterm but have no risk factors. 
However, screening has several 
limitations. Most important, a change in 
CL indicates that the process of cervical 
ripening has already begun. Many 
women with a short cervix will not 
deliver early and thus will receive serial 
monitoring and interventions 
unnecessarily. The ultrasonographer 
must be trained and demonstrate 
expertise in measurement of CL. In 
addition, there are significant costs 
related to equipment and errors in 
interpretation. Ideally, a test that 
predicts PTB before a significant change 
in CL occurs would allow the most time 
for intervention. 
 
Management 
Awareness 
Many of our patients are unaware of the 
risk factors for or causes of PTB. 
Women can be highly motivated to 
avoid PTB but they do not always have 
adequate information. We can teach all 
patients, especially high-risk women, 
about the causes of PTB and the need 
for self-monitoring.  Most women are not 
aware of their own level of risk for PTB, 
and risky behaviors may continue as a 
result of inadequate knowledge.33 Based 
on screening assessments, we should 
provide each patient with her own 
personal risk for PTB and engage her as 
a proactive partner in preventing PTB.9 
With better awareness of risk, 
physicians and patients are in a better 
position to target optimal weight 
management, and to tackle smoking 
cessation and avoidance of drugs and 
alcohol. As an example, aggressive 
programs for smoking cessation can 
include education and behavioral 
counseling, as well as pharmacological 
intervention.9,34,35 
Progestins 
Current recommendations of the 
American Congress of Obstetricians and 
Gynecologists (ACOG) include offering 
treatment with weekly injectable 17 
alpha-hydroxyprogesterone-caproate 
(17-OHP) starting at 16 to 20 weeks’ 
gestation for women with a history of 
PTB.36,37 For women with a short cervix 
(< 15 mm), providing daily vaginal 
progesterone well before contractions or 
other symptoms of parturition begin may 
delay the onset of PTB.17 
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Progestins are currently our best 
intervention, but we still have much to 
learn about them. Even the basic 
mechanism of action is not well 
understood. Manuck, Lai et al. are 
evaluating methods for identifying 
women who are likely to respond to 
progesterone.38 Remaining questions 
include the optimal dose, best vaginal 
preparation of progesterone (gel vs 
micronized), and effect of BMI on 
administration and effectiveness.39 
Cerclage 
It has been recommended to offer 
prophylactic cerclage to women with a 
history of cervical insufficiency,40 and 
offer ultrasonographically-indicated 
cerclage to women with a short cervix 
(<15mm) and a history of PTB.25,41 
An alternative for patients who wish to 
avoid surgery or who are poor surgical 
candidates is a vaginal pessary. In a 
recent randomized trial, pessaries 
demonstrated similar effectiveness to 
cerclage and vaginal progesterone 
strategies in women with singleton 
pregnancy, previous spontaneous PTB 
and short cervix.42 Unfortunately we do 
not have direct comparison trials 
between progesterone, cerclage and 
pessary for patients at risk. 
Care Management 
Prematurity prevention programs have 
been investigated by several 
centers.24,43,44,45,46,47 Increased contact 
with physicians and nurses in a 
specialized PTB clinic decreases the 
rate of PTB.48,49 Compared with the 
current standard of care, a preterm 
prevention clinic resulted in prolongation 
of pregnancy by 1 week and reduction in 
a measure of composite morbidity from 
16.3% to 5.7%, illustrating that an 
aggressive, comprehensive approach in 
a collaborative model including the 
primary physician and maternal-fetal-
medicine specialist can prolong 
pregnancy.50 
Specialty prematurity prevention clinics 
are staffed by or offer access to social 
workers, case managers, nutritionists, 
genetic counselors, telemedicine 
providers, and other skilled individuals 
who can address issues related to 
adequate transportation, safe and 
affordable housing, domestic violence 
counseling, and obtaining prescription 
medications. This type of care 
management can ensure that patients 
are compliant with regular treatment and 
evidence-based interventions such as 
17-OHP.51 Among women on 
progestins, a simple check-in by 
telephone decreased the rate of PTB 
(<35 weeks) by 50%.49 Case 
management based on Medicaid status 
reduced the rate of PTB at 24-28 weeks 
and reduced NICU days, saving millions 
of dollars.48 
Other Interventions 
Screening for asymptomatic bacteriuria 
is required during pregnancy. Screening 
and eliminating cervicitis has also been 
shown to reduce PTB.52 
For women in whom PTB appears 
imminent, effective interventions include 
corticosteroids for acceleration of fetal 
pulmonary maturation and MgSO4 for 
neuroprotection for women between 24 
and 32 weeks’ gestation.53,54,55 
Tocolysis may be given for up to 48 
hours to facilitate these treatments.56 
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Checking fetal fibronectin every 2 weeks 
from 24 to 32 weeks, in the highest risk 
patients, is not currently the standard of 
care, but may facilitate appropriate 
administration of corticosteroids when 
necessary. 
The Future 
Paradigm Shifts 
Prenatal care has been traditionally 
focused on identifying and managing 
preeclampsia, which is less common 
than PTB. Introducing the same level of 
surveillance and care for prevention of 
PTB would entail asking patients at 
each visit about signs and symptoms 
such as back pain and cramping, and 
would entail increased visits in the mid-
portion of pregnancy, rather than the 
end. 
Insurance coverage and reimbursement 
strategies that favor improved neonatal 
outcomes could support changes in 
practice that emphasize early 
identification and treatment for women 
at risk for PTB. These might include 
‘Pay-for-Performance’ initiatives aimed 
at improving quality, efficiency and value 
of care. They also include greater 
support for case management, 
pregnancy centering or other evidence-
based care models. Value-based 
payment is accelerating with hospitals 
and health plans; it is likely a matter of 
time for similar models emphasizing 
value and outcomes to impact physician 
payments. 
The ability to predict PTB early in the 
course of pregnancy could markedly 
improve neonatal outcomes. Time-
intensive programs focusing on patient 
education and modification of risk 
factors could be targeted to the correct 
population. Even if we cannot 
substantially decrease the rate of PTB, 
simply increasing the gestational age at 
which it occurs is likely to achieve the 
desired outcomes of reducing disability, 
improving neonatal outcomes, and 
decreasing costs associated with 
PTB.6,8, 55, 56 Identifying patients who are 
at risk for PTB early will allow us to 
improve the availability of care by 
assuring proximity to a tertiary care 
center and giving antenatal 
corticosteroids and MgSO4 for 
neuroprotection as needed.56 
Identifying High-Risk Women Early 
using Newly Developed Methods 
At present, for the majority of patients, 
we have no opportunity to intervene 
because risk factors for PTB are absent. 
Screening for demographic and clinical 
factors alone is not adequate. The 
appearance of symptoms of PTL is too 
late for most evidence-based 
interventions to be effective at stopping 
or delaying PTB, and tocolysis does not 
extend gestational age.9 There are 
many opportunities for basic science 
investigations, including unanswered 
questions about chorioamnionitis, 
premature cervical ripening, genetic 
predisposition and other possible 
triggers for PTB. We must focus on 
early prediction and improved diagnostic 
techniques. An inexpensive and 
accurate way to detect women at risk 
remains a high priority. 
Multi-marker serum proteomics is being 
developed to predict PTB during the 
second trimester.58 Such a test could be 
combined with a treatment algorithm to 
classify women who require more 
intensive surveillance or interventions 
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(Figure 1).  
Attempts to create prognostic models 
are ongoing but are only modestly 
successful.3,59 Early studies are 
exploring genomics as a predictor of 
PTB.,60,61,62 
 
Figure 1. Treatment Algorithm for Focused Risk Management 
Developing accurate biomarkers would 
not only be clinically useful, but could 
speed the progress of research by 
limiting low-risk patients from clinical 
trials. In the past, these studies have 
been diluted by inclusion of women 
unlikely to benefit from the interventions 
studied. If proteomic risk stratification is 
 
Prior Spontaneous PTB?  
Risk Factors? Treat per ACOG 
guidelines 
Higher Risk 
 Screen and treat for  CL, 
infection 
 Continue CL surveillance  
 Refer to maternal-fetal 
specialist 
 Progesterone 
 Fetal fibronectin 
 Consider pessary, tocolysis, 
steroids  
Lower Risk 
 Evaluate symptoms 
 Screen and treat for 
CL/consider pessary 
and/or progesterone if 
short CL 
 Fetal fibronectin 
 Treat as high-risk if CL 
or fFN concerning  
Yes No 
Yes No 
Care as usual 
Validated Biomarker 
Testing 
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successful, trials of treatments to 
prevent PTB and its consequences can 
enroll fewer subjects and be completed 
more economically and quickly.   
Studies of pharmacogenomics would 
also be possible. 
In addition, several new clinical 
interventions are being studied. 
Atosiban is in use in Europe and is 
being explored as a tocolytic.63 Early 
treatment of vaginal infections with 
antibiotics and the use of probiotics are 
likewise under investigation. 
Comparisons between pessary, 
cerclage and vaginal progestins are also 
underway. 
Conclusions 
Celebration may be premature for the 
recent decrease in the rate of PTB. The 
results of our current treatments are 
inadequate. The recent small decrease 
in the rate of PTB is primarily related to 
changes in physician behavior and 
elective inductions.64 
Can we do better? We can’t keep doing 
what we are doing and expect success. 
We have to change behavior. With 
passionate advocacy and out-of-the-box 
strategy, we can do better. This was 
proven in France through 
implementation of an aggressive and 
comprehensive health policy for the 
prevention of preterm delivery directed 
at all pregnant women—not just women 
considered to be at high risk. With this 
aggressive and comprehensive 
approach, the proportion of deliveries 
before 37 weeks decreased from 8.2% 
in 1972 to 4.9% in 1988—a 41% 
reduction—and the proportion of 
deliveries before 34 weeks decreased 
from 2.4% in 1972 to .09% in 1988—a 
96% reduction.65, 66 
We need an aggressive and 
comprehensive approach to see a 
dramatic reduction in rates of preterm 
delivery in the U.S. The road to a 
primary prevention strategy is long. Until 
primary prevention is possible, we must 
treat PTB as a complex, multifactorial 
condition that demands multifaceted 
solutions: 
• Identify at-risk patients early so 
that treatment can begin before 
late signs of parturition are 
observed. Aggressively screen 
every patient as early as 
possible, and provide her with an 
individualized assessment of risk. 
• Study neonatal outcomes and 
costs rather than focusing on the 
overall rate of PTB. With the right 
interventions, we may find that 
simply prolonging pregnancy is 
sufficient to impact neonatal 
outcomes, lifelong sequelae, and 
costs of care.6,49 
• Actively educate patients and 
engage them in their care. 
• Use validated biomarker 
approaches to move toward 
early, patient-specific, risk-
specific interventions. 
• Individualize the frequency and 
content of prenatal visits to 
emphasize risk assessment and 
prevention of PTB. 
• Reduce outcome disparities for 
minorities and disadvantaged 
communities 
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• Do the low-cost, low-technology, 
non-glamorous work of 
addressing modifiable risk 
factors: social support, smoking 
cessation, education, intensive 
case management, etc. 
• Maximize use of current 
evidence-based interventions 
such as progesterone, cerclage, 
liberal use of CL, and continue to 
study which populations should 
receive screening and treatment. 
• Build and retain local and 
regional community networks of 
obstetric providers and maternal-
fetal-medicine specialists. 
Streamline referrals, create a 
suite of interventions and 
programs for coordinated, 
collaborative prevention of PTB, 
and provide resources for 
community physicians.  
• Encourage funding agencies to 
allocate more resources to the 
study of prevention of PTB. 
• Encourage patients and ACOG to 
lobby members of Congress for 
additional funding to study 
prevention of PTB. 
Our thanks to Mary Chandler, MD, for her 
editorial support in preparing this article. 
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